The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients

被引:27
作者
Satlin, Michael J. [1 ,6 ]
Soave, Rosemary [1 ,6 ]
Racanelli, Alexandra C. [6 ]
Shore, Tsiporah B. [2 ,6 ]
van Besien, Koen [2 ,6 ]
Jenkins, Stephen G. [3 ,6 ]
Walsh, Thomas J. [1 ,4 ,5 ,6 ]
机构
[1] Weill Cornell Med Coll, Transplantat Oncol Infect Dis Program, Div Infect Dis, New York, NY USA
[2] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA
[3] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
[4] Weill Cornell Med Coll, Dept Pediat, New York, NY USA
[5] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY USA
[6] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA
关键词
Vancomycin-resistant enterococci; bloodstream infections; hematopoietic stem cell transplant recipients; BLOOD-STREAM INFECTION; FEBRILE NEUTROPENIC PATIENTS; ANTIBIOTIC-THERAPY; VRE BACTEREMIA; MORTALITY; CEFTAZIDIME; MANAGEMENT; DOMINATION; IMPACT; FEVER;
D O I
10.3109/10428194.2014.896007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As antimicrobial resistance increases, understanding the current epidemiology of bloodstream infections (BSIs) in hematopoietic stem cell transplant (HSCT) recipients is essential to guide empirical antimicrobial therapy. We therefore reviewed microbial etiologies, timing and outcomes of BSIs in patients who were transplanted from September 2007 to December 2011. Vancomycin-resistant enterococci (VRE) were the most common pathogens in allogeneic HSCT recipients and the fourth most common after autologous transplant. VRE did not cause any of 101 BSIs in neutropenic patients who were not receiving antibacterials, but caused 32 (55%) of 58 BSIs in neutropenic patients receiving a broad-spectrum beta-lactam agent (p < 0.001). Rates of septic shock and 7-day mortality were 5% and 0% for streptococcal bacteremia, 12% and 18% for VRE bacteremia, and 20% and 14% for Gram-negative bacteremia. In conclusion, VRE bacteremia was the most common BSI in allogeneic HSCT recipients, occurred primarily in neutropenic patients receiving broad-spectrum beta-lactams and was associated with poor outcomes.
引用
收藏
页码:2858 / 2865
页数:8
相关论文
共 33 条
[1]   Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients [J].
Almyroudis, NG ;
Fuller, A ;
Jakubowski, A ;
Sepkowitz, K ;
Jaffe, D ;
Small, TN ;
Kiehn, TE ;
Pamer, E ;
Papanicolaou, GA .
TRANSPLANT INFECTIOUS DISEASE, 2005, 7 (01) :11-17
[2]  
[Anonymous], 2006, Management of multidrug-resistant organisms in healthcare settings, 2006
[3]   The rise of the Enterococcus: beyond vancomycin resistance [J].
Arias, Cesar A. ;
Murray, Barbara E. .
NATURE REVIEWS MICROBIOLOGY, 2012, 10 (04) :266-278
[4]   Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course [J].
Avery, R ;
Kalaycio, M ;
Pohlman, B ;
Sobecks, R ;
Kuczkowski, E ;
Andresen, S ;
Mossad, S ;
Shamp, J ;
Curtis, J ;
Kosar, J ;
Sands, K ;
Serafin, M ;
Bolwell, B .
BONE MARROW TRANSPLANTATION, 2005, 35 (05) :497-499
[5]   Heat and chemical resistance of enterococci [J].
Bradley, CR ;
Fraise, AP .
JOURNAL OF HOSPITAL INFECTION, 1996, 34 (03) :191-196
[6]  
Clinical and Laboratory Standards Institute, 2010, M100S20U CLSI
[7]   Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer [J].
Cometta, AF ;
Calandra, T ;
Gaya, H ;
Zinner, SH ;
deBock, R ;
DelFavero, A ;
Bucaneve, G ;
Crokaert, F ;
Kern, WV ;
Klastersky, J ;
Langenaeken, J ;
Micozzi, A ;
Padmos, A ;
Paesmans, M ;
Viscoli, C ;
Glauser, MP ;
Martino, P ;
Caballero, D ;
Engelhard, D ;
Shapiro, M ;
Castagnola, E ;
Massimo, L ;
Giacchino, R ;
Sanz, M ;
Gigium, M ;
Carotenuto, M ;
Lopez, A ;
Andrien, JM ;
Paulus, R ;
Martino, B ;
Nobile, F ;
Togni, P ;
Ferster, A ;
Cudillo, L ;
Legrand, JC ;
Dinota, A ;
Cajozzo, A ;
Quintini, G ;
MartinezDalmau, A ;
Nosari, A ;
Bucaneve, GP ;
Cometta, A ;
Galazzo, M ;
Giddey, M ;
Bille, J ;
Blaser, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1108-1115
[8]   A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia [J].
Del Favero, A ;
Menichetti, F ;
Martino, P ;
Bucaneve, G ;
Micozzi, A ;
Gentile, G ;
Furno, P ;
Russo, D ;
D'Antonio, D ;
Ricci, P ;
Martino, B ;
Mandelli, F .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1295-1301
[9]   Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. [J].
Donskey, CJ ;
Chowdhry, TK ;
Hecker, MT ;
Hoyen, CK ;
Hanrahan, JA ;
Hujer, AM ;
Hutton-Thomas, RA ;
Whalen, CC ;
Bonomo, RA ;
Rice, LB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1925-1932
[10]   GLUCOCORTICOSTEROID THERAPY - MECHANISMS OF ACTION AND CLINICAL CONSIDERATIONS [J].
FAUCI, AS ;
DALE, DC ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (03) :304-315